RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Understanding the Final Guidance on Postmarketing Safety Reporting for Combination Products – An Interactive Analysis with FDA and Industry

RAC Credits
Friday, 15 November 2019 (9:00 AM) - Friday, 15 November 2019 (4:00 PM) Eastern Time (US & Canada)
5635 Fishers Ln
Rockville, Maryland, USA, 20852-1796

On 22 July 2019 FDA issued its much-anticipated Final Guidance on Postmarketing Safety Reporting for Combination Products.  While the final guidance provides several clarifications from the draft guidance and final rule, certain challenges remain with respect to effective implementation of its requirements. Offered in collaboration with the Combination Products Coalition (CPC), this program provides the unique opportunity to work with representatives from FDA, as well as industry veterans, to examine the Final Guidance and find out what your company needs to do to be in compliance by the rule’s effective date of 31 July 2020.

During the workshop you will hear directly from FDA experts regarding key takeaways from the Final Guidance, the Agency’s interpretation of the applicable requirements, and other important topics to anyone who works in this space. This is your chance to submit questions that you have to work through any questions you might have about the Final Guidance, and also let FDA know where additional gaps may exist.

Working in small groups facilitated by industry experts from the CPC, you will use a case study approach to explore concepts from the Final Guidance, identify best practices for effective implementation, and note areas where additional clarity from FDA would be beneficial.  The findings from these case study sessions will be presented to the broader audience and FDA and will be topics for discussion in a closing roundtable session.  Don’t miss this crucial opportunity to provide input on these pivotal issues that could affect you for years to come.

Program Date: 15 November 2019

Meeting Location:

Regulatory Affairs Professionals Society - HQ Office

5635 Fishers Lane, Terrace Level

Rockville, MD 20852

Registration Closes: 8 November 2019

Refund Deadline: 16 October

RAC Credits: 6 RAC recertification credits upon completion of the program

Will this meeting be recorded?    No

Proof of Attendance: An electronic letter of attendance will be sent upon request.

Registration Fees

Registration to 17 October

RAPS Members:  $150

Nonmembers:  $150

Advance registration is required for this workshop. Participants are encouraged to register early. Onsite registrations are not accepted.


  • Understand key takeaways from the Final Rule and best practices for risk management.
  • Assess challenges to effective implementation and address remaining gaps.
  • Discuss potential solutions and recommendations that will require FDA and industry collaboration.

Who Should Attend

This program is intended for individuals working at all professional levels in the drug, device, biologic, and combination product space.  Anyone involved in post-market safety, pharmacovigilance, medical device reporting, and all other quality, regulatory, or compliance issues will greatly benefit from attending.


  • Examining the Final Rule and Draft Guidance (Panel Discussion)
  • Case Study, Session 1
  • Case Study, Session 2
  • Review of Case Study Findings

NOTE: Program content may vary


  • Khaudeja Bano, MD – head of medical affairs, postmarketing safety working group, chair, Abbott Diagnostics
  • Melissa Burns, program coordinator, office of combination products, US FDA 
  • John (Barr) Weiner – general attorney, office of combination products, US FDA 
  • Maureen Melvin – supervisory health science, office of surveillance and epidemiology, US FDA 
  • Suranjan De – deputy director, center for drugs evaluation and research, US FDA 

IMPORTANT: Attendees must bring their own laptops. RAPS does not provide equipment for attendees.

Advance registration is required for this workshop. Participants are encouraged to register early. Onsite registrations are not accepted.

Registration Form

If it is your preference, please use the registration form to register by mail, email or fax. A RAPS online account will be created to complete your purchase if you are not a member or past customer.


Call RAPS Solution Center at +301.770.2920, ext. 200.

Refund Deadline: 16 October

Other Information

RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation.

Program Contact 

Nichelle Sankey


+301 770 2920, ext. 291


Paid parking is available in the parking ramp directly behind 5635 Fishers Lane in Rockville (next door to US Pharmacopeial Convention).

Area Airports

Ronald Reagan Washington National Airport (24 miles)

Washington Dulles International Airport (36 miles)

Baltimore-Washington International Airport (37 miles)

Area Hotels

Even Hotel Rockville (Walking Distance)

1775 Rockville Pike

Rockville, MD 20852

Reservations: +1 877 834 3613

Hilton Washington DC/Rockville Hotel (Walking Distance)

1750 Rockville Pike

Rockville, MD 20852

Reservations: +1 301 468 1100

Bethesda North Marriott Hotel

701 Marinelli Road

Bethesda, MD 20852

Reservations: +1 301 822 9200

Bethesda Marriott Suites

6711 Democracy Boulevard

Bethesda, MD 20817

Reservations: +1 800 228 9290

Washington Metro Access

The Twinbrook Metro Station is a short walk to 12601 Twinbrook Parkway. Take the Red Line to the Twinbrook Metro Station.


All cancellation requests must be submitted to raps@raps.org by 16 October. RAPS is unable to accept cancellations by phone. Please specify the name of the person registered and event title. A 20% cancellation fee will be assessed.

Substitutions may be accepted with written approval from RAPS, and must be submitted to raps@raps.org by 1 November.

If you have questions or concerns, please contact RAPS customer service at +301 770 2920, ext. 200, or via email at raps@raps.org.

NOTE: RAPS reserves the right to request additional documentation in making determinations regarding cancellations and refunds. Refunds will be granted solely at the discretion of RAPS.